|
|||||
|
|
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents,and tiotropium versus placebo in COPD patients |
|
| Affiliation: | 1. Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, UK;2. Allergy Department, Odense University Hospital, Odense, Denmark;3. Pulmonary Department, Mainz University Hospital, Mainz, Germany;4. Novartis Pharma AG, Basel, Switzerland;5. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA |
| Abstract: | |
| Keywords: | Glycopyrronium Indacaterol Pooled analysis QVA149 Safety Tiotropium |
| 本文献已被 ScienceDirect 等数据库收录！ | |